pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,117 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1174Endpoints893BioPharma Dive344BioSpace310Fierce Biotech290onclive165raps106globenewswire health73
therapy area
allOncology7617Rare Disease1875Cardiology1743Immunology1482Hematology1323Vaccines1197Pulmonology
  • Study finds researchers become less disruptive as they age, favoring incremental work
    A new study published in Science reports that scientists tend to produce their most disruptive work early in their careers, but shift toward less groundbreaking research as they get older. The ana…
    STAT · 4mo agoNeutral↗ source
  • CDC’s cruise ship health chief Luis Rodríguez retires amid hantavirus outbreak on MV Hondius
    The Centers for Disease Control and Prevention announced that Luis Rodríguez, who has been with the Vessel Sanitation Program since 2010 and its chief since 2023, will retire. His departure comes…
    STAT · 4mo agoNeutral↗ source
← prev
page 113 of 125
next →
fda recalls70
fda medwatch60
fda press38
1188
Psychiatry & CNS866
Ophthalmology496
Pain480
Endocrinology & Metabolism474
Infectious Disease444
STAT+: FDA revisits a rare cancer treatment it rejected a few months ago
Secret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The Readout
STAT · 4mo ago↗ source
  • Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
    There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an a…
    Endpoints · 4mo ago↗ source
  • STAT+: OpenAI’s health policy wishlist, CGM news from Dexcom, and more
    In this edition of STAT Health Tech: A health policy blueprint from OpenAI, CGM updates from Dexcom, and push back against whole body scans.
    STAT · 4mo ago↗ source
  • Pennsylvania sues AI chatbot company for posing as a licensed doctor
    The state of Pennsylvania has sued Character.AI, a startup that lets users chat with different AI-generated personas, for illegally presenting a chatbot as a licensed doctor in the state. This is t…
    Endpoints · 4mo ago↗ source
  • STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
    The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
    STAT · 4mo ago↗ source
  • Hospital shootings steadily increased since 2000
    What the FDA has lost, why hantavirus isn't the next pandemic, and more health news from Morning Rounds
    STAT · 4mo ago↗ source
  • STAT+: Next-gen Duchenne drug from Entrada disappoints
    A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.
    STAT · 4mo ago↗ source
  • Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst
    Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s po…
    Endpoints · 4mo ago↗ source
  • STAT+: Color me skeptical: Drinking gold is not an ALS cure
    In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.
    STAT · 4mo ago↗ source
  • STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
    The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1 billion.
    STAT · 4mo ago↗ source
  • STAT+: What was lost at the FDA
    What was lost at the FDA: A year after DOGE’s cuts, six agency staffers describe the work they never thought they’d leave.
    STAT · 4mo ago↗ source
  • Opinion: Eugene Braunwald, ‘father of modern cardiology,’ told me he had two dreams. One came true
    Legendary cardiologist Eugene Braunwald had two visions for his career. One of them came true.
    STAT · 4mo ago↗ source
  • Cruise ship hantavirus outbreak worries experts, though they discount pandemic fears
    Scientists are worried that hantaviruses haven’t been as well studied as they ought to be, but not that the MV Hondius cruise ship is ground zero for the next pandemic.
    STAT · 4mo ago↗ source
  • STAT+: Oregon hospitals won’t outsource to national physician chain after all
    Faced with stiff local opposition and a possible loss in court, PeaceHealth drops plan to replace Eugene Emergency Physicians with staffing chain ApolloMD.
    STAT · 4mo ago↗ source
  • Trump administration’s drug strategy is at odds with recent actions on funding, policy
    The White House nods to medication-assisted treatment and fentanyl test strips, despite recently placing new limits.
    STAT · 4mo ago↗ source
  • Amgen, AbbVie say IRA negotiations impacted Q1 sales
    At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January. Amgen and AbbVie reported in thei…
    Endpoints · 4mo ago↗ source
  • Lilly plans new $4.5B manufacturing investment in Indiana
    Eli Lilly is committing to its roots, allocating $4.5 billion for new manufacturing investments across Indiana as drugmakers pledge more US projects. The world’s largest pharma company, headquarter…
    Endpoints · 4mo ago↗ source
  • BeOne culls five cancer programs and an autoimmune Phase 2
    BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experi…
    Endpoints · 4mo ago↗ source
  • Lonza looks to ride ADC wave with upcoming factory, workforce expansion
    BASEL, Switzerland — Lonza said it wants to own the commercial market for antibody-drug conjugates, with a new manufacturing site set to come online next year and plans to increase its headcount. T…
    Endpoints · 4mo ago↗ source
  • STAT+: Administration report on most favored nation drug pricing raises new details — and questions
    Administration report on most-favored nation drug pricing raises new details — and questions.
    STAT · 4mo ago↗ source
  • STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review
    Sanofi has asked the FDA to pull its type 1 diabetes drug out of Commissioner Marty Makary’s new speedy drug review program.
    STAT · 4mo ago↗ source
  • Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
    Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’
    Color Health, which coordinates cancer screening, is moving into a gap it observed — obtaining and coordinating actual cancer care.
    STAT · 4mo ago↗ source